Optimization of velocity receptor transduction in CAR T cells | bioRxiv
Limited infiltration capacity significantly limits the effectiveness of chimeric antigen receptor (CAR) T cells for solid tumors. We have recently developed a large family of highly modular synthetic cytokine receptors termed velocity receptors (VRs), capable of binding key inflammatory cytokines, such as IL5, IL8, and TNFα, which drive CAR T cells into an elevated motility state. These new CAR T cells sense and amplify these autocrine secreted cytokines, thereby maintaining a self-propelled, high migratory state, facilitating penetration into dense tumor cores. In this study, we systematically evaluated key factors influencing VR transduction in order to improve their stable integration and expression. We established a dual-fluorescence reporter system to allow simultaneous monitoring of both VR and CAR constructs, and while evaluating modifications to the vector construct and generating standardized infectious unit (IFU) curves under various conditions. Our results demonstrate that the attempt to reduce overall lentiviral vector size by eliminating non coding sections upstream of the central polypurine tract (cPPT) do not yield better transduction efficiency, though it is unclear if the effect is due to viral production or integration impairment. We also observed a log-linear relationship between viral dose and transduction efficiency for a subset of VRs previously tested in various mouse models of human cancer, with VR5αIL8 and VR5αTNFα VRs consistently outperforming VR5αIL5 and V5 (full length native IL5 receptor). Overall, these findings establish an optimized and reproducible framework that offers valuable guidance for the future development and functional study of VR–CAR T cells in cellular therapies for solid tumors. ### Competing Interest Statement The authors have declared no competing interest. National Institutes of Health, https://ror.org/01cwqze88, U54CA268083, RO1CA300052, UG3CA275681 Patrick C. Walsh Prostate Cancer Research Fund United States Department of Defense, HT9425-25-1-0688
Optimization of velocity receptor transduction in CAR T cells | bioRxiv Skip to main content New Results Optimization of velocity receptor transduction in CAR T cells Xinyun Jiang , Vasco Queiroga , Eban A. Hanna , Denis Wirtz doi: https://doi.org/10.1101/2025.10.05.680548 Xinyun Jiang 1 Institute for Nanobiotechnology, The Johns Hopkins University , Baltimore, 21218, Maryland, USA Find this author on Google Scholar Find this author on PubMed Search for this author on this site Vasco Queiroga 1 Institute for Nanobiotechnology, The Johns Hopkins University , Baltimore, 21218, Maryland, USA 2 De
Explore this link on the map →related reading
- Teaching an old dog new tricks: next-generation CAR T cells | British Journal of Cancernature.com
- Medicine's Endgamenotboring.co
- Immunotherapy in pediatric malignancies: current status and future perspectives - PMCncbi.nlm.nih.gov
- Cancer cells educate natural killer cells to a metastasis-promoting cell state - PMCpmc.ncbi.nlm.nih.gov
- Cancer cells educate natural killer cells to a metastasis-promoting cell state - PubMedpubmed.ncbi.nlm.nih.gov
- 癌症治療的海豹特種部隊 淺談CAR-T細胞治療法::台灣癌症基金會canceraway.org.tw
- Interferon-alpha/beta receptor - Wikipediaen.wikipedia.org
- The blood cancer that became solvableworksinprogress.news
- Arc Institute’s first virtual cell model: <span style="font-variant: small-caps">S<span style="font-weight: bolder">tate</span></span> | Arc Institutearcinstitute.org
- Clinical use of lentiviral vectors | Leukemianature.com
- Immunotherapy for Cancer - NCIcancer.gov
- Checking your browser - reCAPTCHAncbi.nlm.nih.gov